ID
29542
Beskrivning
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Pneumonia Assessment
Nyckelord
Versioner (2)
- 2018-03-21 2018-03-21 -
- 2018-04-05 2018-04-05 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
5 april 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463
Similar models
Pneumonia Assessment
- StudyEvent: ODM
C0024117 (UMLS CUI-2)
C0220825 (UMLS CUI-3)
C0031809 (UMLS CUI-4)
C0574845 (UMLS CUI [1,2])
C0200949 (UMLS CUI [1,2])
C0032285 (UMLS CUI [1,3])
C1515974 (UMLS CUI [1,2])
C0086388 (UMLS CUI [1,2])
C0205721 (UMLS CUI [2])
C0032285 (UMLS CUI [1,2])
C0032285 (UMLS CUI [1,2])
Inga kommentarer